Article published in Genetic Engineering & Biotechnology News (GEN)
LBG’s Georgia Sloboda and Patrick Falvey were asked to share their insights on the CDMO selection process with author Vivienne Raper in an article published in Genetic Engineering & Biotechnology News (GEN).
The article, which is titled “COVID-19 Pandemic Boosted Industry Engagement with CDMOs,” explores recent trends in the industry, including companies turning to alternative CDMOs due to a shortage of CDMO capacity during the pandemic.
“[The pandemic] forced companies to look at alternatives [and that] gave a huge opportunity for companies, who had less of a [famous] name or [large] capacity, to really shine and deliver for their clients,” notes Sloboda in the article.
Ms. Sloboda and Mr. Falvey, who are recognized as SMEs in the field, discussed the CDMO selection process in a presentation at CPHI Frankfurt in November.
Ms. Sloboda has more than 30 years of experience in the biotechnology/pharmaceutical industry with emphasis in the vaccines and oncology space. Her background includes experience in Quality Operations, Quality Systems and Compliance, Board of Health Inspection Management, Manufacturing Operations/Tech Transfer, CMO Oversight, and Regulatory Compliance.
Mr. Falvey has more than 30 years of research, managerial, and technical experience in the pharmaceutical and biotechnology industries. He has held various positions of responsibility and leadership in Operations, Quality Assurance, and Compliance and believes in collaboration among individuals and groups to effect positive change.
“Georgia and Patrick share their thoughts on industry trends and best practices when working with CDMOs,” says Peter Latham, Founding Partner, LBG. “Their insights on the subject include more than 50 years of combined experience highlighting the importance of cultural fit and relationships in a world that is sometimes focused on promised pricing and timelines.”
